- Home
- ORLA vs DNLI Comparison
ORLA vs DNLI Comparison
Compare ORLA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORLA | DNLI |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Canada | United States |
| Employees | 354 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ORLA | DNLI |
|---|---|---|
| Price | $13.06 | $18.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $27.00 | ★ $32.58 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2239.45 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $772,153,000.00 | N/A |
| Revenue This Year | $183.80 | N/A |
| Revenue Next Year | $36.88 | $3,993.60 |
| P/E Ratio | $82.46 | ★ N/A |
| Revenue Growth | ★ 145.83 | N/A |
| 52 Week Low | $5.25 | $10.57 |
| 52 Week High | $14.36 | $24.35 |
Technical Indicators
Market Signals| Indicator | ORLA | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 51.69 |
| Support Level | $11.99 | $17.20 |
| Resistance Level | $14.36 | $20.61 |
| Average True Range (ATR) | 0.65 | 1.03 |
| MACD | -0.08 | -0.21 |
| Stochastic Oscillator | 53.23 | 29.72 |
Price Performance
Historical ComparisonAbout ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.